Studies of isogenic non-small-cell lung cancer cell lines harboring different KRAS G12C, G12D, or G12V mutations revealed differential metabolic signatures related to enhanced amino acid catabolism, altered lipid biochemistry and altered antioxidant program [8]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.